Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859621 | 0.82 | AKR1C3 (0.43) | ADRB1ADRB3AKR1C3PLAAT3PLAAT5 | |
| SCHEMBL5725348 | 0.79 | ALDH1A1 (0.44) | ADRB1ADRB3PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL5726791 | 0.78 | NAAA (0.46) | ADRB1ADRB3PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL5726132 | 0.76 | ALDH1A1 (0.46) | ADRB1ADRB3PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL5046905 | 0.75 | TAS2R14 (0.50) | AKR1C3PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL7986084 | 0.75 | SMN1; SMN2 (0.56) | PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2 | |
| SCHEMBL5043229 | 0.75 | TAS2R14 (0.40) | AKR1C3PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL2769588 | 0.74 | TAS2R14 (0.39) | AKR1C3PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5726420 | 0.73 | TAS2R14 (0.41) | AKR1C3PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5727230 | 0.73 | TAS2R14 (0.39) | AKR1C3PLAAT3PLAAT5PLAAT2PLAAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | ADRB1 622/4885ADRB3 800/4885AKR1C3 2233/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | ADRB1 162/4885ADRB3 203/4885AKR1C3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.